{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-008051","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.451976+00:00","generated_at":"2026-06-06T02:02:44.715714+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GNI Group FY2023 revenue up 49% to ¥26.0B; Gyre expects Hydronidone IND in 2024; settles litigation for $385K","bullets":["GNI Group FY2023 revenue ¥26,010M (+49% YoY), operating profit ¥13,108M (+851%), net profit ¥9,504M vs loss prior year.","Basic EPS ¥169.50; FY2024 guidance: revenue ¥39,566M (+52%), operating profit ¥16,286M.","Gyre expects to submit Hydronidone IND in US by end of 2024; Phase 3 trial in China last patient observation in 2024.","Gyre (as successor to Catalyst) settles shareholder litigation over business combination; pays $385K in attorneys' fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-008051","json":"https://secwatch.observer/filing/0001140361-24-008051.json","markdown":"https://secwatch.observer/filing/0001140361-24-008051.md","text":"https://secwatch.observer/filing/0001140361-24-008051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/0001140361-24-008051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/ef20021723_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:02:44.715714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66cd4700bf18288a55a755f5e56656f672cc1e25","claim":"GYRE THERAPEUTICS, INC. reported FY2023 (January to December) results: revenue 26,010, net income 9,504, EPS 169.50. Guidance reaffirmed.","evidence_excerpt":"Profit attributable to owners of the parent Total comprehensive income for the year Million yen % Million yen % Million yen % Million yen % Million yen % Million yen % FY2023 26,010 49.3 13,108 851.3 12,612 - 9,504 - 8,094 - 10,662 - FY2022 17,418 37.3 1,377 (15.2) 767 (30.6) (868) - 388 (63.5) 187 (88.1) Basic earnings per share Diluted earnings per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/0001140361-24-008051-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023 (January to December)"},{"label":"Revenue","value":"26,010"},{"label":"Net income","value":"9,504"},{"label":"EPS","value":"169.50"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}